Functionally, OKT-3/IL-15-expanded Vδ1 cells exhibited highly consistent innate cytotoxicity against a range of hematological and solid tumor targets, including T cell leukemia Jurkat cells, cervical cancer HeLa cells, neuroblastoma LAN-1 cells, chronic myelogenous leukemia K562 cells and acute myeloid leukemia NOMO-1 cells (Figure 2E). This evidence concerns the gene IL15 and acute myeloid leukemia.